**Protocol Title:** Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with Nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

**Target Population:** Stage IV Pancreatic Ductal Adenocarcinoma
- Hyaluronan (HA)-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma (PDA)

**Summary:** The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with Nab-Paclitaxel plus Gemcitabine (PAG Treatment), compared with Placebo combined with Nab-Paclitaxel plus Gemcitabine (AG Treatment). Participants will be randomized in a 2:1 ratio to PAG or AG Treatment.

**Key Inclusion Criteria:**
- Stage IV Pancreatic Ductal Adenocarcinoma (PDA) with histological confirmation of PDA via archived or fresh core biopsy of either the Primary Tumor or 1 Metastatic Site.
- Participants must be determined to be Hyaluronan-High based on tumor biopsy.
- At least 1 tumor metastasis measurable on CT Scan and / or MRI, excluding the Primary Pancreatic Lesion.
- If a participant has had adjuvant / neoadjuvant therapy and / or therapy for locally advanced disease (chemotherapy for non-metastatic Pancreatic Cancer in combination with or without radiation therapy), tumor recurrence or disease progression must have occurred no sooner than 6 Months after completing the last dose of the aforementioned therapies, provided all toxicities have returned to baseline or ≤ Grade 1.
- ECOG Performance Score of 0 or 1.

**Key Exclusion Criteria:**
- Clinical evidence of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or other known Thromboembolic (TE) event present during the screening period.
- Previous Radiotherapy, Surgery, Chemotherapy, or Investigational Therapy for the treatment of Metastatic Disease.
  - Palliative Radiotherapy for pain control or metastatic bone lesions is allowed.
- Known Central Nervous System involvement or Brain Metastases.
- New York Heart Association Class III or IV cardiac disease or myocardial infarction within the past 12 Months.
- History of Cerebrovascular Accident or Transient Ischemic Attack.
- Clinically significant pre-existing carotid artery disease.

**Contacts:**
- **Principal Investigator:** Robert Ramirez, DO
- **Research Nurses (RN):** April Wendt (awendt@ochsner.org, ext. 24548)
  Sharon Jerdonek (sharon.jerdonek@ochsner.org, ext. 23929)

**For additional information:** [https://clinicaltrials.gov/ct2/show/NCT02715804](https://clinicaltrials.gov/ct2/show/NCT02715804)